ライフサイエンスコーパス: non-small-cell

1 and confirmed in 1,828 patients (1,563 with non-small cell LC and 265 with small cell LC).

2 ic and radiomic features in CT images of 258 non-small cell lung adenocarcinomas.

3 east cancer on DCE-MRI in 65 studies and (3) non-small cell lung cancer (adenocarcinomas) from benign

4 ed malignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC).

5 ted into small cell lung cancer (n = 57) and non-small cell lung cancer (n = 33).

6 nd OS, respectively) in early-stage I and II non-small cell lung cancer (NSCLC) after resection.

7 egrated with these workflows, we analyzed 32 non-small cell lung cancer (NSCLC) and 22 breast cancer

8 a (SqCC) are the two predominant subtypes of non-small cell lung cancer (NSCLC) and are distinct in t

9 Dose-dependent synergy was observed in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Squ

10 one of the most frequently mutated genes in non-small cell lung cancer (NSCLC) and is commonly comut

11 on of Notch signaling is a common feature of non-small cell lung cancer (NSCLC) and is correlated wit

12 the YEATS2 gene is highly amplified in human non-small cell lung cancer (NSCLC) and is required for c

13 astasis suppressor 1 (BRMS1) is decreased in non-small cell lung cancer (NSCLC) and other solid tumor

14 lecule inhibitor directed against HuR, using non-small cell lung cancer (NSCLC) as a model.

15 edle aspiration (EBUS-TBNA) in patients with non-small cell lung cancer (NSCLC) can facilitate the se

16 d using exploratory factor analysis for 2139 non-small cell lung cancer (NSCLC) cases and 2163 freque

17 mall molecule inhibitor (HL001) that induces non-small cell lung cancer (NSCLC) cell cycle arrest and

18 ng stem cell marker Lgr6 becomes enriched in non-small cell lung cancer (NSCLC) cells during malignan

19 eliver siRNA to cytoplasm of KRAS mutant H23 Non-Small Cell Lung Cancer (NSCLC) cells for oncogene kn

20 MUC1-C induces MYC expression in KRAS mutant non-small cell lung cancer (NSCLC) cells, an effect that

21 gration and invasion in KRAS- or EGFR-mutant non-small cell lung cancer (NSCLC) cells.

22 ss of its protein (BRG1) occur frequently in non-small cell lung cancer (NSCLC) cells.

23 igenic function that drives the phenotype of non-small cell lung cancer (NSCLC) cells.

24 ine whether radiomics features measured from non-small cell lung cancer (NSCLC) change during therapy

25 Non-small cell lung cancer (NSCLC) comprises 85-90% of l

26 st-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearran

27 ntation within the tumor microenvironment in non-small cell lung cancer (NSCLC) has not yet been adeq

28 ts with breast cancer and 9634 patients with non-small cell lung cancer (NSCLC) in our regression and

29 Non-small cell lung cancer (NSCLC) is characterized by e

30 Non-small cell lung cancer (NSCLC) is heterogeneous in t

31 tumorigenicity, invasion, and metastases in non-small cell lung cancer (NSCLC) lines.

32 g CRISPR, shRNA, and expression screens in a non-small cell lung cancer (NSCLC) model.

33 p = 0.001), but the worst OS was observed in non-small cell lung cancer (NSCLC) patients (HR = 3.11,

34 ngitudinal blood samples from advanced stage non-small cell lung cancer (NSCLC) patients (n = 29) rec

35 quantitative whole-body (18)F-FDG metrics in non-small cell lung cancer (NSCLC) patients as a functio

36 response are unpredictable in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with

37 nalysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with

38 Non-small cell lung cancer (NSCLC) patients with tumors

39 irst time, to our knowledge, in stage III-IV non-small cell lung cancer (NSCLC) patients.

40 culturing DCs with pooled sera from multiple non-small cell lung cancer (NSCLC) patients.

41 predict poor long-term survival in resected non-small cell lung cancer (NSCLC) patients.

42 uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients.

43 tatic (18)F-FDG PET for tumor delineation in non-small cell lung cancer (NSCLC) radiation therapy pla

44 d was used on the plasma of 48 patients with non-small cell lung cancer (NSCLC) to detect EGFR mutati

45 e clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum

46 exome sequencing analysis of an EGFR-mutant non-small cell lung cancer (NSCLC) tumor biopsy from a p

47 Purpose To investigate whether non-small cell lung cancer (NSCLC) tumors that express h

48 Identification of patients with early stage non-small cell lung cancer (NSCLC) with high risk of rec

49 ) imaging in determining the nodal status of non-small cell lung cancer (NSCLC) with the aim of eluci

50 e widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have

51 own to be effective in a subset of melanoma, non-small cell lung cancer (NSCLC), and kidney cancers.

52 he definitive management of locally advanced non-small cell lung cancer (NSCLC), but long-term prospe

53 st commonly inactivated tumor suppressors in non-small cell lung cancer (NSCLC), especially in tumors

54 for the HDI-based anticancer therapeutics in non-small cell lung cancer (NSCLC), in the present study

55 he most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung can

56 Among them, 20 studies of melanoma, non-small cell lung cancer (NSCLC), or renal cell carcin

57 To improve treatment outcomes in non-small cell lung cancer (NSCLC), preclinical models t

58 nce of subtype-specific prognostic genes for non-small cell lung cancer (NSCLC), we had previously pr

59 enerated by RNA sequencing for patients with non-small cell lung cancer (NSCLC).

60 ncogenes has revolutionized the treatment of non-small cell lung cancer (NSCLC).

61 in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC).

62 n with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC).

63 d with one common strategy remain unclear in non-small cell lung cancer (NSCLC).

64 telet indices and prognosis in patients with non-small cell lung cancer (NSCLC).

65 with chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC).

66 ield of the most common type of lung tumors, non-small cell lung cancer (NSCLC).

67 RNA termed GAS5-AS1 as a tumor suppressor in non-small cell lung cancer (NSCLC).

68 and metformin is an effective treatment for non-small cell lung cancer (NSCLC).

69 tant metastasis in patients with early-stage non-small cell lung cancer (NSCLC).

70 ressed and correlates with poor prognosis in non-small cell lung cancer (NSCLC).

71 d marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).

72 MYC-oncogenic alterations commonly found in non-small cell lung cancer (NSCLC).

73 environment and blood serum of patients with non-small cell lung cancer (NSCLC).

74 oncogenic role in mediating tumorigenesis in non-small cell lung cancer (NSCLC).

75 activity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC).

76 ighest signal was detected in a patient with non-small cell lung cancer (SUVmax, 10.9; T/B ratio, 8.4

77 In this study, we analysed LSD1 function in non-small cell lung cancer adenocarcinomas.

78 min, exhibits efficacy in pancreatic cancer, non-small cell lung cancer and breast cancer.

79 l neoantigens were identified in early-stage non-small cell lung cancer and expressed high levels of

80 SMARCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell

81 e impact on tumorigenesis in mouse models of non-small cell lung cancer and melanoma, loss of both bl

82 vegetables" pattern, and stronger for other non-small cell lung cancer and never smokers for the "Am

83 inhibitor resistance mechanisms.EGFR-mutant non-small cell lung cancer are often resistant to EGFR t

84 ing of forty-seven patients with early-stage non-small cell lung cancer before and after three weeks

85 82 cluster are significantly co-repressed in non-small cell lung cancer cell lines and primary tumors

86 ule targeting reduced mitogenic signaling in non-small cell lung cancer cell lines, suggesting that t

87 tor receptor (EGFR) inhibitor, erlotinib, in Non-Small Cell Lung Cancer cell lines.

88 n vitro system to delineate their effects on non-small cell lung cancer cell proliferation and apopto

89 elivery of siRNA to undruggable KRAS mutated non-small cell lung cancer cells would sensitize the cel

90 in nanosomes was assessed in H1299 and A549 non-small cell lung cancer cells, normal MRC9 lung fibro

91 73 patients with advanced non-small cell lung cancer from the prospective multicen

92 uch as CTLA-4 and PD-1 can cure melanoma and non-small cell lung cancer in a subset of patients.

93 We report here a novel orthotopic model of non-small cell lung cancer in rats, where we have studie

94 outcomes of patients diagnosed with stage 1 non-small cell lung cancer in the NLST to a nationally r

95 that downregulation of LZTFL1 expression in non-small cell lung cancer is associated with recurrence

96 imply that resistance to targeted therapy in non-small cell lung cancer is highly dynamic, and also o

97 , we evolved resistance in an ALK rearranged non-small cell lung cancer line (H3122) to a panel of 4

98 eby limiting its utility in the treatment of non-small cell lung cancer metastases in the brain.

99 Non-small cell lung cancer patients carrying oncogenic E

100 for chemotherapy combined with radiation in Non-Small Cell Lung Cancer patients for use in clinical

101 non-smoker or former light smoker, advanced non-small cell lung cancer patients of Asian origin.

102 Three hundred forty-eight non-small cell lung cancer patients underwent diagnostic

103 ors prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activatin

104 d radiomic features for somatic mutations in non-small cell lung cancer patients.

105 nd after 7-10 d of erlotinib treatment in 50 non-small cell lung cancer patients.

106 odistribution and dosimetry of (18)F-FAZA in non-small cell lung cancer patients.

107 onse on a later CT scan in erlotinib-treated non-small cell lung cancer patients.

108 radication of double-positive human NCI-H358 non-small cell lung cancer target tumors over single-pos

109 rther shown that knock-out of YAP sensitizes non-small cell lung cancer to EGFR inhibitor Erlotinib.

110 The high genomic instability of non-small cell lung cancer tumors leads to the rapid dev

111 Eleven patients with inoperable non-small cell lung cancer underwent 2-5 thoracic PET/MR

112 Ten patients diagnosed with advanced non-small cell lung cancer underwent subsequent dynamic

113 patients referred for the initial staging of non-small cell lung cancer underwent whole-body imaging

114 logically proven or radiologically suspected non-small cell lung cancer were prospectively enrolled i

115 ublicly available gene expression dataset of non-small cell lung cancer when combined with the existi

116 In contrast, a non-small cell lung cancer xenograft expressing a consti

117 ring a subcutaneous HER3 overexpressing H441 non-small cell lung cancer xenograft.

118 with previously treated advanced KRAS-mutant non-small cell lung cancer, addition of selumetinib to d

119 ential immune target in melanoma, but not in non-small cell lung cancer, and implicates SPAG5 as an a

120 ar survival rates of small cell lung cancer, non-small cell lung cancer, and non-lung cancer patients

121 In non-small cell lung cancer, anti-PD-1 antibodies have be

122 Eighty-six patients with non-small cell lung cancer, colorectal liver metastases,

123 , an antiprogrammed cell death-1 therapy for non-small cell lung cancer, from May 2012 to September 2

124 inally identified as a prognostic marker for non-small cell lung cancer, in cerebrovascular pathogene

125 proven pancreatic cancer, laryngeal cancer, non-small cell lung cancer, prostate cancer, melanoma, b

126 he NLST group undergoing surgery for stage 1 non-small cell lung cancer, those in the SEER-Medicare N

127 le of this phenomenon occurs in ALK-positive non-small cell lung cancer, where targeted therapies are

128 ework in the specific context of EGFR-driven non-small cell lung cancer, which is commonly treated wi

129 r administering immunotherapy in early-stage non-small cell lung cancer.

130 inhibitor used as second-line treatment for non-small cell lung cancer.

131 GFR) inhibitors remains a major challenge in non-small cell lung cancer.

132 ways and are associated with smoking-related non-small cell lung cancer.

133 l growth factor receptor-targeted therapy in non-small cell lung cancer.

134 (TBP) and Importin 8 (IPO8) to be stable in non-small cell lung cancer.

135 potential as a new therapeutic approach for non-small cell lung cancer.

136 ytes and peripheral blood from patients with non-small cell lung cancer.

137 ve the diagnostic accuracy of the staging of non-small cell lung cancer.

138 prognostic biomarkers of prostate cancer and non-small cell lung cancer.

139 r heterogeneity and evolution in early-stage non-small cell lung cancer.

140 18)F-FDG PET quantification in patients with non-small cell lung cancer.

141 of advanced melanoma, renal cell cancer, and non-small cell lung cancer.

142 nd KRAS are now routine in the management of non-small cell lung cancer.

143 potential treatment strategy for KRAS mutant non-small cell lung cancers (NSCLC) and colorectal carci

144 rospective study, 36 patients with stage III non-small cell lung cancers (NSCLC), who underwent dynam

145 on mutation of LKB1, frequently occurring in non-small cell lung cancers (NSCLCs), is a predominant c

146 serial histologic sections from 90 archival non-small cell lung cancers from January 1, 2008, to Dec

147 In murine models of small-cell and non-small cell lung cancers, including patient-derived x

148 nt target for upregulation by mutant KRAS in non-small cell lung cancers.

149 Phase I/II clinical trial investigations for non-small cell lung cancers.

150 ntegrative genomic and proteomic analysis of non-small cell lung carcinoma (NSCLC) cell lines reveale

151 This method was applied to human non-small cell lung carcinoma (NSCLC) cell lines, embedd

152 ated death worldwide, and among this cancer, non-small cell lung carcinoma (NSCLC) comprises the majo

153 ted from static and parametric PET images of non-small cell lung carcinoma (NSCLC) in order to provid

154 othymidine ((18)F-FLT) PET in advanced-stage non-small cell lung carcinoma (NSCLC) patients with an a

155 umor-driving genes in patients with advanced non-small cell lung carcinoma (NSCLC), especially in tho

156 dazole ((18)F-FMISO) uptake in patients with non-small cell lung carcinoma (NSCLC).

157 PET metrics and histopathologic response in non-small cell lung carcinoma (NSCLC).

158 sms by which EZH2 expression is regulated in non-small cell lung carcinoma cells by oncogenic KRAS.

159 to induce DNA damage associated apoptosis in non-small cell lung carcinoma.

160 on polymerase chain reaction analyses of 102 non-small cell lung tumors, 61 ovarian tumors, 70 liver

161 a, glioblastoma multiforme, prostate tumors, non-small cell lung tumors, and ovarian tumors, but not

162 reatic (IRR, 2.07; 95% CI, 1.95 to 2.20) and non-small-cell lung (IRR, 1.69; 95% CI, 1.54 to 1.86) ca

163 pture CTCs from metastatic breast, colon and non-small-cell lung (NSCLC) cancer patients.

164 TEP-based detection of early- and late-stage non-small-cell lung cancer (n = 518 late-stage validatio

165 e-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC) (Radiation Therapy On

166 nostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases.

167 metabolism, thereby selectively sensitizing non-small-cell lung cancer (NSCLC) and glioblastoma (GBM

168 idermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) are associated with p

169 for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-pacli

170 alf of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured.

171 ed or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyro

172 nts who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pemb

173 ort that CLCb is specifically upregulated in non-small-cell lung cancer (NSCLC) cells and is associat

174 n K-Ras-independent, but not K-Ras-dependent non-small-cell lung cancer (NSCLC) cells.

175 ading cause of cancer deaths worldwide, with non-small-cell lung cancer (NSCLC) constituting more tha

176 Non-small-cell lung cancer (NSCLC) demonstrates remarkab

177 Non-small-cell lung cancer (NSCLC) diagnosed in young pa

178 Purpose Multiple agents for advanced non-small-cell lung cancer (NSCLC) have been approved in

179 Non-small-cell lung cancer (NSCLC) is globally prevalent

180 e to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%.

181 anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.

182 ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK t

183 RT) -associated cardiac injury for stage III non-small-cell lung cancer (NSCLC) is unclear, but highe

184 after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at

185 expression profiling of individual CTCs from non-small-cell lung cancer (NSCLC) patients with remarka

186 (TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients.

187 eceiving anti-PD-1 or anti-PD-L1 therapy for non-small-cell lung cancer (NSCLC) presented hair repigm

188 proved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated wi

189 juvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest sur

190 improves efficacy in the first-line advanced non-small-cell lung cancer (NSCLC) setting.

191 Here, we analyzed non-small-cell lung cancer (NSCLC) specimens and cell li

192 oint inhibitors has changed the landscape of non-small-cell lung cancer (NSCLC) therapy, with 2 appro

193 ed in both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) to try to improve inc

194 and its clinical-pathologic significance in non-small-cell lung cancer (NSCLC) was investigated.

195 nhibitor approved for patients with advanced non-small-cell lung cancer (NSCLC) whose epidermal growt

196 y in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cel

197 the treatment of all patients with advanced non-small-cell lung cancer (NSCLC), but is most active i

198 Among patients with non-small-cell lung cancer (NSCLC), data on intratumor h

199 increasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMRT and three-dimen

200 or locally advanced or incompletely resected non-small-cell lung cancer (NSCLC), it remains uncertain

201 have shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with sq

202 L1) blockade, have improved the treatment of non-small-cell lung cancer (NSCLC), supporting the premi

203 Here, in elderly patients with advanced non-small-cell lung cancer (NSCLC), we compared a standa

204 nib in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC), who had progressed a

205 tical component in the care of patients with non-small-cell lung cancer (NSCLC), yet cardiac injury a

206 oncogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC).

207 rove local tumor control of locally advanced non-small-cell lung cancer (NSCLC).

208 ted with platinum resistance and survival in non-small-cell lung cancer (NSCLC).

209 taxel among patients with previously treated non-small-cell lung cancer (NSCLC).

210 ate metabolism and are frequently mutated in non-small-cell lung cancer (NSCLC).

211 ient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer (NSCLC).

212 rain metastases in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).

213 h previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC).

214 in previously treated patients with advanced non-small-cell lung cancer (NSCLC).

215 gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC).

216 LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC).

217 rst-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC).

218 durable clinical responses in patients with non-small-cell lung cancer (NSCLC).

219 atients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC).

220 nase (ALK) gene associated with ALK-positive non-small-cell lung cancer (NSCLC).

221 ver docetaxel in previously treated advanced non-small-cell lung cancer (NSCLC).

222 patients with ALK-rearranged (ALK-positive) non-small-cell lung cancer (NSCLC).

223 predictive roles of TP53, KRAS, and EGFR in non-small-cell lung cancer (NSCLC).

224 proved as second-line treatment for advanced non-small-cell lung cancer (NSCLC).

225 X-2) has been implicated in cell invasion in non-small-cell lung cancer (NSCLC).

226 that imparts a robust anti-tumor effect for non-small-cell lung cancer (NSCLC).

227 of patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC).

228 2) has been associated with worse outcome in non-small-cell lung cancer (NSCLC).

229 adaptor that we have shown is important for non-small-cell lung cancer (NSCLC).

230 systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC).

231 arget for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

232 tients with advanced squamous or nonsquamous non-small-cell lung cancer (NSCLC).

233 iously treated BRAF(V600E)-mutant metastatic non-small-cell lung cancer (NSCLC).

234 Metastatic squamous non-small-cell lung cancer (SQ NSCLC) is a serious and l

235 patients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other sol

236 8 years with ALK-rearranged stage IIIB or IV non-small-cell lung cancer (with at least one measurable

237 Patients with inoperable stage III or IV non-small-cell lung cancer and cachexia (defined as >/=5

238 onist, on cachexia in patients with advanced non-small-cell lung cancer and cachexia.

239 cers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma.

240 ion of relapse following primary surgery for non-small-cell lung cancer and the characterization of e

241 We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutati

242 0 years of age with newly diagnosed advanced non-small-cell lung cancer benefit from platinum-based c

243 Non-small-cell lung cancer biopsy specimens from 2011 to

244 c, data-driven approach, utilizing 106 human non-small-cell lung cancer cell lines, was used to inter

245 g is recapitulated in mutant KRAS homozygous non-small-cell lung cancer cells and in vivo, in spontan

246 fic cell-autonomous addiction of KRAS-mutant non-small-cell lung cancer cells to receptor-dependent n

247 the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx

248 Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the E

249 Non-small-cell lung cancer is the leading cause of cance

250 ple EGFR tyrosine kinase inhibitor-resistant non-small-cell lung cancer models.

251 clinical specimens obtained from EGFR-mutant non-small-cell lung cancer patients with acquired EGFR t

252 Non-small-cell lung cancer patients with activating epid

253 a method to quantify radiosensitivity in 134 non-small-cell lung cancer patients, by using K-Means cl

254 and carboplatin-paclitaxel in patients with non-small-cell lung cancer receiving thoracic radiation.

255 vival according to the time interval between non-small-cell lung cancer resection and the initiation

256 efficacious when started 7 to 18 weeks after non-small-cell lung cancer resection.

257 Patients who recover slowly from non-small-cell lung cancer surgery may still benefit fro

258 ereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer was reviewed for developmenta

259 t of platinum-based adjuvant chemotherapy in non-small-cell lung cancer were used as part of the LACE

260 ired to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted t

261 apy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed

262 ment-naive patients with completely resected non-small-cell lung cancer who received postoperative mu

263 n: Patients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases now hav

264 Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at l

265 als were eligible for inclusion, 42 (39%) in non-small-cell lung cancer, 36 (33%) in breast cancer, 2

266 zumab is used in advanced melanoma, advanced non-small-cell lung cancer, and in head and neck cancer.

267 ntitumor immunity in patients with melanoma, non-small-cell lung cancer, and renal cell cancer.

268 d controlled trials of systemic therapies in non-small-cell lung cancer, breast cancer, colorectal ca

269 rgeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data

270 nalling pathway is frequently deregulated in non-small-cell lung cancer, often through KRAS activatin

271 vival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expressi

272 ed patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had

273 ocetaxel in previously treated patients with non-small-cell lung cancer.

274 al activity, in patients with ALK-rearranged non-small-cell lung cancer.

275 combination therapies) for stage IIIB or IV non-small-cell lung cancer.

276 e prognostic marker for survival in resected non-small-cell lung cancer.

277 has been referred for treatment of advanced non-small-cell lung cancer.

278 benefit to a number of staging scenarios in non-small-cell lung cancer.

279 t of patients with operable locally advanced non-small-cell lung cancer.

280 n expressed by many solid tumours, including non-small-cell lung cancer.

281 ess in the treatment of EGFR mutant positive non-small-cell lung cancer.

282 handgrip, strength in patients with advanced non-small-cell lung cancer.

283 therapy (SBRT) for patients with early-stage non-small-cell lung cancer.

284 OHHLA, we find that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated w

285 se, and it is often genetically activated in non-small-cell lung cancers (NSCLCs) by, for instance, m

286 We previously reported that human non-small-cell lung cancers (NSCLCs) oxidize glucose in

287 idermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been

288 RET rearrangements are found in 1-2% of non-small-cell lung cancers.

289 , investigating adjuvant therapy in resected non-small-cell lung cancers.

290 SCO) adjuvant therapy guideline for resected non-small-cell lung cancers.

291 Non-small-cell lung carcinoma (NSCLC) accounts for 85% o

292 Our current study using non-small-cell lung carcinoma (NSCLC) cell lines, animal

293 roves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epiderm

294 cember 2013, solid tumour samples (including non-small-cell lung carcinoma [NSCLC], colorectal carcin

295 Finally, we found that non-small-cell lung carcinoma that presented a cytonucle

296 ach for treating aggressive cancers, such as non-small-cell lung tumors and metastatic melanoma.

297 ere noted in human orthotopic pancreatic and non-small-cell lung xenograft models, expanding use and

298 diagnosed with cancer (prostate, colorectal, non-small-cell lung, non-Hodgkin lymphoma, breast, uteri

299 diagnosed with advanced breast, colorectal, non-small-cell lung, or pancreatic cancer from 2009 to 2

300 In NQO1(+) cancers, such as non-small-cell lung, pancreatic, and breast cancers, cel